Photograph of Alexis J. Gilman

Alexis J. Gilman


Companies seeking antitrust clearance for their mergers and acquisitions, or that are parties or third parties in investigations and litigation launched by the Federal Trade Commission, the Antitrust Division of the Department of Justice, or state attorneys general, turn to Alexis Gilman for experienced and effective antitrust counsel. Alexis leverages years of experience at the FTC, including three years as head of a merger division, to represent clients in a broad range of antitrust and competition matters, including antitrust diligence, merger reviews and clearances, government investigations, Hart-Scott-Rodino and foreign premerger notifications, civil conduct matters, general antitrust compliance and trade association counseling, and antitrust litigation. Having advised clients that range from Fortune 100 firms to not-for-profit entities, his experience spans a wide range of industries, including health care, retail, consumer goods, food and beverage, distribution services, veterinary services, casinos and gaming, pharmaceuticals, biotechnology, digital health, technology products and services, and energy, among others.  

Alexis’ practice has a particular focus on representing merging parties and third parties in merger investigations by the FTC, DOJ, and state attorneys general. He brings significant prior government experience and knowledge to his client work, having joined the firm after seven years at the FTC, where, as assistant director, he led the 30-attorney Mergers IV Division and worked on some of the agency’s highest-profile matters. While at the FTC, he also had leading roles in and oversaw investigations and litigations in various industries, including hospitals and other health care providers, distribution services, retail, consumer goods, food and beverage, supermarkets, funeral homes, casinos, and online gaming. Prior to this position, he served as a deputy assistant director of the division from 2012 to 2014 and as a staff attorney in the division from 2010 to 2012.

Prior to joining the FTC, Alexis was an associate in the Antitrust Group of a large U.S.-based international law firm, where he represented Fortune 500 companies in U.S. and foreign merger investigations and other civil antitrust matters. He represented pharmaceutical, publishing, retail, chemical, energy, and private equity clients, among others.

Alexis is a frequent speaker at the ABA, American Health Law Association, and other organization events. He received his J.D. with honors from The George Washington University Law School, where he was a member of the George Washington International Law Review. He received his B.A. from Williams College. Alexis is originally from Maine.


  • Williams College, B.A. (1996)
  • The George Washington University Law School, J.D. (2002) With Honors


Professional Activities and Memberships

  • Member of the American Bar Association and its Antitrust, Litigation, Business, and Health Law Sections
  • Member of The American Health Law Association and its Antitrust, Business Law and Governance, and In-House Counsel Practice Groups
  • Member of the Hispanic National Bar Association

View More


Antitrust and Competition

Mergers and Acquisitions

Antitrust Investigations

Litigation & Trial

Coronavirus (COVID-19) Response Team

Health Care Antitrust Practice

Civil Antitrust Litigation

Antitrust and Technology

Antitrust Mergers and Acquisitions

Private Equity

Show more practices…

  • Representing a third party in the FTC’s investigation and litigation of NVIDIA’s proposed acquisition of Arm Ltd.
  • Represented Dorel Industries in the sale of its Dorel Sports segment to Pon Holdings P.V. for $810 million.
  • Represented Novant Health in its $5 billion acquisition of New Hanover Regional Medical Center, the largest hospital acquisition in North Carolina history. 
  • Represented NorthCrest Health in its sale to HCA’s TriStar Health.
  • Represented a veterinary-services provider in its acquisition of nearly 50 facilities from a multi-regional provider.
  • Represented Summa Health in its proposed affiliation with Beaumont Health (subsequently abandoned).
  • Represented a financial-services firm and its portfolio company in obtaining clearance from the FTC of an acquisition in an area subject to a Prior Notice requirement.
  • Represented a leading global manufacturer and marketer of branded consumer foods as a third party in an FTC merger investigation.
  • Represented a marketer and seller of consumer products as a third party in an FTC merger investigation and litigation.
  • Represented a multinational Fortune 20 healthcare services company as a third party in an FTC conduct investigation and litigation.
  • Represented AT&T in its successful defense of the DOJ’s suit challenging its $108 billion acquisition of Time Warner.
  • Represented a Fortune 100 healthcare services company as a third party in an FTC merger investigation.
  • Represented a grocery retailer as a third party in an FTC supermarket merger investigation.
  • Represented an office products distributor as a third party in an FTC office supplies merger investigation.
  • Counseled a national transportation-services provider and energy industry trade association on antitrust compliance issues.
"FTC Hears Mixed Views at Public Forum on Proposed Rule to Ban Non-Compete Agreements," Antitrust Law Alert (February 28, 2023). Contacts: Jeane A. Thomas, CIPP/E, Alexis J. Gilman, Olivier N. Antoine, Megan L. Wolf, Shawn R. Johnson, Richard Stella
Client Alert / Newsletter
Practitioners Sceptical About “Sudden” DOJ Policy Statement Withdrawals Global Competition Review (February 9, 2023)
Press Coverage
"Court Rejects FTC’s Bid to Block Meta’s Proposed Acquisition of VR Fitness App Developer," Antitrust Law Alert (February 8, 2023). Contacts: Jeane A. Thomas, CIPP/E, Alexis J. Gilman, Olivier N. Antoine, Richard Stella
Client Alert / Newsletter
"DOJ Withdraws “Safety Zones” for Information Sharing and Other Collaborations," Antitrust Law Alert (February 6, 2023). Contacts: Stefan M. Meisner, Shawn R. Johnson, Alexis J. Gilman, Olivier N. Antoine, Troy A. Barsky, Ashley (Lee) McMahon
Client Alert / Newsletter
2022's Biggest Antitrust Developments And What To Expect In 2023 (podcast) AHLA's Speaking of Health Law (January 31, 2023)
Press Coverage
"FTC Cracks Down on Non-Competes as Unfair Methods of Competition," Antitrust Law Alert (January 6, 2023). Contacts: Alexis J. Gilman, Jeane A. Thomas, CIPP/E, Megan L. Wolf, Kate M. Watkins, Lauren T. Fleming
Client Alert / Newsletter
"FTC Proposes Rule to Categorically Ban Non-Compete Agreements," Antitrust Law Alert (January 6, 2023). Contacts: Alexis J. Gilman, Shawn R. Johnson, Kris D. Meade, Megan L. Wolf, Jeane A. Thomas, CIPP/E, Christopher J. Banks, Richard Stella, Rachel Lesser, Jessica Franzetti
Client Alert / Newsletter
"FTC Issues New Policy Statement on “Rigorous Enforcement” Against Unfair Methods of Competition," Antitrust Law Alert (November 15, 2022). Contacts: Jeane A. Thomas, CIPP/E, Shawn R. Johnson, Alexis J. Gilman, Lauren T. Fleming
Client Alert / Newsletter
Kroger-Albertsons Antitrust Review Likely To Focus On Local Store Overlap The Wall Street Journal (October 21, 2022)
Press Coverage
The Best Lawyers in America 2023 Recognizes 54 Crowell & Moring Attorneys, Three Selected as Lawyer of the Year (August 18, 2022)
Firm News / Announcement

For all Highlights, News & Knowledge, please click here to view desktop bio.

Crowell & Moring LLP is an international law firm with offices in the United States, Europe, MENA, and Asia that represents clients in litigation and arbitration, regulatory and policy, and transactional and corporate matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation and government-facing matters, as well as its ongoing commitment to pro bono service and diversity, equity, and inclusion.

View Desktop Site | Mobile Sitemap |

Contact | Subscribe | Terms of Use | Privacy Statement | Alumni

© Crowell & Moring LLP 2023
Attorney advertising - prior results do not guarantee a similar outcome.